RGBP (Regen BioPharma) Beneish M-Score: -13.01 (As of Jun. 26, 2026)

What is Regen BioPharma Beneish M-Score?

Regen BioPharma RGBP +33.33% Beneish M-Score is -13.01 as of Jun. 26, 2026. The stock has 7 warning signs investors should review. Among 831 Biotechnology companies, Regen BioPharma ranks better than 98.8% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -13.01 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Regen BioPharma's Beneish M-Score or its related term are showing as below:

RGBP' s Beneish M-Score Range Over the Past 10 Years
Min: -300.18 Med: -13.01 Max: 6.78
Current: -13.01

During the past 13 years, the highest Beneish M-Score of Regen BioPharma was 6.78. The lowest was -300.18. And the median was -13.01.

Regen BioPharma Beneish M-Score Related Terms

Regen BioPharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Beneish M-Score Chart

Regen BioPharma Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

Beneish M-Score

Get a 7-Day Free Trial

-4.80

-54.21

-16.16

-0.61

-4.55

Regen BioPharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Beneish M-Score	Get a 7-Day Free Trial															-2.74	-4.88	-4.55	-12.45	-13.01

RGBP vs ENDV, ADTX, SCPX: Beneish M-Score Comparison

For the Biotechnology subindustry, Regen BioPharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Beneish M-Score falls into.

Save Embed

Regen BioPharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Regen BioPharma for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.7333

0.528 * 1

0.404 * 0

0.892 * 1

0.115 * 1

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 1.6413

4.679 * -2.311538

0.327 * 0.6224

-13.01

This Year (Mar26) TTM:

Last Year (Mar25) TTM:

Total Receivables was $0.26 Mil.
Revenue was 0.059 + 0.059 + 0.059 + 0.059 = $0.24 Mil.
Gross Profit was 0.059 + 0.059 + 0.059 + 0.059 = $0.24 Mil.
Total Current Assets was $0.26 Mil.
Total Assets was $0.26 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $0.88 Mil.
Total Current Liabilities was $5.62 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was 0.992 + -0.968 + -0.572 + -0.167 = $-0.72 Mil.
Non Operating Income was 1.182 + -0.381 + -0.349 + -0.089 = $0.36 Mil.
Cash Flow from Operations was -0.063 + -0.198 + -0.16 + -0.056 = $-0.48 Mil.

Total Receivables was $0.15 Mil.
Revenue was 0.059 + 0.059 + 0.059 + 0.059 = $0.24 Mil.
Gross Profit was 0.059 + 0.059 + 0.059 + 0.059 = $0.24 Mil.
Total Current Assets was $0.15 Mil.
Total Assets was $0.17 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $0.54 Mil.
Total Current Liabilities was $5.87 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0.26 / 0.236)	/	(0.15 / 0.236)
	=	1.101695	/	0.635593
	=	1.7333

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0.236 / 0.236)	/	(0.236 / 0.236)
	=	1	/	1
	=	1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (0.26 + 0) / 0.26)	/	(1 - (0.152 + 0) / 0.169)
	=	0	/	0.100592
	=	0

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0.236	/	0.236
	=	1

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0 / (0 + 0))	/	(0 / (0 + 0))
	=		/
	=	1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(0.883 / 0.236)	/	(0.538 / 0.236)
	=	3.741525	/	2.279661
	=	1.6413

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0 + 5.619) / 0.26)	/	((0 + 5.868) / 0.169)
	=	21.611538	/	34.721893
	=	0.6224

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-0.715 - 0.363	-	-0.477)	/	0.26
	=	-2.311538

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Regen BioPharma has a M-score of -13.01 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -13.01 mean?

Regen BioPharma (RGBP) has a Beneish M-Score of -13.01 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #10 out of 831 companies in the Biotechnology industry, placing it in the top 1.2%.

Is Regen BioPharma's Beneish M-Score too high?

Regen BioPharma's current Beneish M-Score is -13.01. Based on the distribution chart, Regen BioPharma ranks #10 out of 831 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.

How does Regen BioPharma's Beneish M-Score compare to ENDV and ADTX?

According to the Biotechnology industry distribution chart, Regen BioPharma ranks #10 out of 831 companies for Beneish M-Score. This places Regen BioPharma in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current Beneish M-Score is -13.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Regen BioPharma stock overvalued right now?

Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Beneish M-Score is -13.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Beneish M-Score is -13.01 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Industry Healthcare Biotechnology

Comparable Companies ENDV ADTX SCPX IOBTQ CNBX SIGY CARM CYTOF LIPO WINT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges RGBPP.PFD:USA

Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942

Website https://www.regenbiopharmainc.com

Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.